4,901 trials
Multiple Myeloma
Primary: Geometric Mean Maximum Observed Serum Concentration (Cmax) of Elotuzumab Following Cycle 1, Day 1 Dose Administration - Grouping by Cockcroft-Gault Creatinine Clearance…
Chronic Myeloid Leukemia · Acute Lymphoblastic Leukemia
Primary: Summary of Nilotinib Non-compartmental PK Parameters: Cmax — 405.111; 402.715 ng/mL
Healthy
Primary: Cmax for Serum Deferiprone — 3.89; 2.76; 3.02; 13.89 μg/mL
Healthy
Primary: Percentage of Subjects With Drug-related Adverse Events — 16.7; 44.4; 11.1 Percentage of participants
Multiple Myeloma
Primary: Number of Participants With Serious Adverse Events (SAEs), Adverse Events (AEs) Leading to Discontinuation, Deaths — 2; 3; 1; 3 participants
Pharmacokinetics
Primary: Number of Participants Who Experienced One or More Adverse Events (AEs) — 4; 5; 5; 5 Participants
Pneumonia
Primary: Maximum Observed Plasma Concentration (Cmax) of CP-70429 Following CP-70,429 Intravenous Dose — 17700; 22070; 28940; 10340 nanogram per milliliter (ng/mL)
Renal Insufficiency
Primary: AUC 0-tz of Afatinib (BIBW 2992) — 948; 952; 776; 634 ng*h/mL
Malaria
Primary: OZ439 Cmax — 1600; 824; 616; 1530 ng/mL
Alcohol-related Disorders · Post-traumatic Stress Disorder
Primary: Clinician-administered PTSD Scale (CAPS) — 58.89; 40.22 units on a scale — p=.028
Hepatitis B, Chronic
Primary: Mean Change From Baseline in Viral Quantitative e Antibody — 0.07; 0.15; 0.02; 0.03 Cut-off index (C.O.I.)
Gastrointestinal Bleeding
Primary: Number of Participants With Side-Effects — 10 participants
Cystic Fibrosis
Primary: Pharmacokinetic Assessment of a 5 Day Infusion of Gallium Nitrate (IV Ganite®) — 503; 537 ug*hr/mL
Colorectal Cancer
Primary: Area Under The Plasma Concentration-Time Curve From Zero To Infinity (AUC0-Inf) of 5'-Deoxy-5-fluorouridine 5'-(DFUR) — 13605; 12177; 11817 ng/mL*hr
HIV Infections
Primary: Area Under the Plasma Concentration-Time Curve From Time of Administration to 12 Hours After Dosing (AUC 0-12h) of Saquinavir (SQV) and Ritonavir (RTV) — 28518; 24332…